- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04252209
the Effect of Mixture of Natural Products As Salivary Substitutes in Treatment Of Xerostomia (RCT)
the Effect of Mixture of Natural Products As Salivary Substitute In Comparison To Carboxy Methyl Cellulose In Treatment Of Xerostomia In Patients With Sjogren's Syndrome: Cross Over Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be held in the Rheumatology clinic at El Kasr Al-Ainy Cairo University Hospital in patients with Sjogren's syndrome. Population: A random sample of adult patients diagnosed with primary or secondary Sjogren's syndrome attending at the Rheumatology clinic in El Kasr Al-Ainy, Cairo University Hospital will be enrolled in the study in a consecutive order.
The interventions will be in the form of gel to be maintained for long period in the oral cavity. The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%. The control is also a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
Both gels had similar appearance, color, smell, and weight. They will be produced by professional pharmacist in faculty of pharmacy, Al Azher university, Cairo, Egypt.it was taken from previous study with modification in percentage of aloe vera and adding coconut oil. Both gels will be applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep . The same individuals will deliver the trial interventions in all study groups, both gels will be used for 2 weeks then washout period for 7 days then cross over them. Modification of life style will be promoted as daily tooth brushing, hydration with sufficient amounts of water, eating fibrous food as fruits and vegetables, avoid any alcohol mouth wash or any other topical oral products. The medication will be withdrawn if any allergic reaction occurs.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 020
- Faculty of Dentistry, Cairo Univeristy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients
- Patients physically able to participate in the clinical trial.
- Patients diagnosed with Sjogren's syndrome using 2016 ACR/EULAR classification criteria (Shiboski et al., 2017).
- Secondary sjogren patients with rheumatoid arthritis.
- Patients with clinical oral dryness positive scores.
Exclusion Criteria:
- Patients with previous radiotherapy.
- Patients not approved to participate in the clinical trial.
- Patients didn't complain from xerostomia.
- Patients with diabetes mellitus.
- Patients taking drugs caused xerostomia as antidepressants, anticholinergics, antihistamines, and anxiolytics and antihypertensives (Campos et al., 2019).
- Patients with symptomatic oral lesions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: patients with sjogren's received natural mixture
The intervention is a moisturizing gel containing 10% aloe vera jelly, 10% coconut oil, 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%. applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep |
mixture of herbal oils of coconut, peppermint, aloe vera
Other Names:
|
Active Comparator: patients with sjogren's recievrd CMC
the control is a moisturizing gel containing 3% peppermint essential oil, 3% carboxy methyl cellulose, 10% propylene glycol, and 0.1% potassium sorbate and water up to 100%. applied topically in all surfaces of oral mucosa 4 times daily after eating and before sleep |
a moisturizing gel contained 3%carboxy methyl cellulose, 3% peppermint essential oil, 10% propylene glycol, 0.1% potassium sorbate, and water up to 100%.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
subjective oral dryness
Time Frame: 14 days
|
subjective oral dryness measured by bother 1 scale.
It is patient centered scale as the patient reported how much he suffer from oral dryness on scale from 1 - 10.as 1 mean mild dryness and 10 mean severe oral dryness
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
objective oral dryness
Time Frame: 14 days
|
using the Challacombe Scale.
It will be assessed by the investigator in the first visit (baseline assessments before the interventions) and in the end of two weeks (final assessments).as
score 1 mean mild oral dryness and score 10 mean severe oral dryness
|
14 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Arthritis, Rheumatoid
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Sjogren's Syndrome
- Xerostomia
Other Study ID Numbers
- OMD3-7-2 CairoU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sjogren's Syndrome
-
The Cleveland ClinicBristol-Myers SquibbWithdrawnRheumatoid Arthritis | Inflammatory Arthritis | Primary Sjogren's Syndrome | Secondary Sjogren's SyndromeUnited States
-
RemeGen Co., Ltd.RecruitingPrimary Sjogren's SyndromeChina
-
Stanford UniversityWithdrawnPrimary Sjogren's Syndrome
-
Matthew C. BakerWithdrawnPrimary Sjogren's SyndromeUnited States
-
University College, LondonCambridge University Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals... and other collaboratorsActive, not recruitingSjogren's Syndrome Childhood-onsetUnited Kingdom, Ireland
-
Keio UniversityUnknown
-
Parion SciencesCompletedXerostomia | Dry Mouth Associated With Sjogren's SyndromeUnited States
-
University Hospital MuensterNovartisCompletedPrimary Sjogren's SyndromeGermany
-
Akdeniz UniversityCompleted
Clinical Trials on natural herbs of coconut, aloe vera, and pepperint
-
University of ThessalyCompletedPerformance | Skeletal Muscle Damage | Exercise-induced Aseptic InflammationGreece
-
Cairo UniversityUnknown
-
Cairo UniversityUnknown
-
Government Dental College and Research Institute...Completed
-
Damascus UniversityCompleted
-
University of Santiago de CompostelaAlfonso X El Sabio UniversityCompleted
-
Organon and CoCompleted
-
Zainab J AbbasCompleted
-
Organon and CoCompleted
-
Imam Abdulrahman Bin Faisal UniversityCompleted